![Simon Cooper](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Simon Cooper
Technik-/Wissenschafts-/F&E-Leiter bei
MORC HOLD
Profil
Simon Cooper is currently Chief Medical Officer at Morphic Therapeutic, Inc. and Morphic Holding, Inc., both since 2024.
Former positions include Chief Medical Officer at Keros Therapeutics, Inc. from 2021 to 2024, Chief Medical Officer at Anokion US, Inc. from 2019 to 2021, Chief Medical Officer & Senior Vice President at Kadmon Holdings, Inc. in 2021, VP, Global Project Head-Immunology & Inflammation at Sanofi, and Global Program Medical Director at Novartis International AG from 2012 to 2014.
Education includes undergraduate studies at Newcastle University Medical School.
Aktive Positionen von Simon Cooper
| Unternehmen | Position | Beginn |
|---|---|---|
| MORC HOLD | Technik-/Wissenschafts-/F&E-Leiter | 19.03.2024 |
Morphic Therapeutic, Inc.
 Morphic Therapeutic, Inc. BiotechnologyHealth Technology Researches and develops small molecules to block transmembrane integrin receptors | Technik-/Wissenschafts-/F&E-Leiter | 01.03.2024 |
Ehemalige bekannte Positionen von Simon Cooper
| Unternehmen | Position | Ende |
|---|---|---|
| KEROS THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 12.03.2024 |
| KADMON HOLDINGS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2021 |
Anokion US, Inc. | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2021 |
Novartis International AG
 Novartis International AG Pharmaceuticals: MajorHealth Technology Offers healthcare solutions | Corporate Officer/Principal | 01.07.2014 |
| SANOFI | Corporate Officer/Principal | - |
Ausbildung von Simon Cooper
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
5
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Offers healthcare solutions | Health Technology |
Sanofi
 Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
Kadmon Holdings, Inc.
 Kadmon Holdings, Inc. BiotechnologyHealth Technology Discovers, develops and delivers transformative therapies for unmet medical needs | Health Technology |
Morphic Therapeutic, Inc.
Morphic Therapeutic, Inc. BiotechnologyHealth Technology Researches and develops small molecules to block transmembrane integrin receptors | Health Technology |
Keros Therapeutics, Inc.
 Keros Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics for muscle diseases | Health Technology |
Morphic Holding, Inc.
 Morphic Holding, Inc. Pharmaceuticals: MajorHealth Technology Develops oral integrin drugs | Health Technology |
Newcastle University Medical School
 Newcastle University Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Anokion US, Inc. | Electronic Technology |
